Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Pembrolizumab in Advanced Malignancies
NCT03407976Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in malignant neoplasms (advanced stage), urothelial carcinoma (UC), solid tumor and 2 more, sponsored by University of Utah. Primary endpoints: Dose Limiting Toxicities at 21 days and Objective Response Rate at 12 months. Started Jun 2018; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
malignant neoplasms (advanced stage)urothelial carcinoma (UC)solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03407976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407976.